References
- Russo EB. Cannabinoids in the management of difficult to treat pain. Ther. Clin. Risk Manag.4, 245–249 (2008).
- Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int. J. Clin. Pract.59, 291–295 (2005).
- Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Mult. Scler.12, 646–651 (2006).
- Pérez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today42, 495–501 (2006).
- Stott CG, Wright S, Guy GW. A comparison of pharmacokinetic profiles of inhaled δ-9-tetrahydrocannabinol (THC) from smoked cannabis with Sativex® oromucosal spray in humans: implications for possible symptomatic treatment in multiple sclerosis. Eur. J. Neurol.15(Suppl. 3), 365 (2008).
- Potter DJ, Clark P, Brown MB. Potency of δ 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J. Forensic Sci.53, 90–94 (2008).
- Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses66, 234–246 (2006).
- Collin C, Davies P, Mutiboko IK, Ratcliffe S; for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol.14, 290–296 (2007).
- Collin C, Ehler E, Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res.32, 451–459 (2010).
- Novotna A, Mares J, Ratcliffe S et al. Arandomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. DOI: 10.1111/j.1468-1331.2010.03328.x (2011) (Epub ahead of print).
- Montalbán X, Wright S. Trial period for new symptomatic treatments: lessons learnt from a Sativex in MS spasticity clinical trial. Mult. Scler.15, S272 (2009).
- Wade D, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler.10, 434–441 (2004).
- Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler.12, 639–645 (2006).
- Collin C, Serpell M, Potts R. Results of an open-label extension trial of Sativex (THC:CBD) in patients with multiple sclerosis and symptoms of spasticity. Mult. Scler.13, S129 (2007).
- Schoedel K, Chen N, Guy GW et al. Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users. Eur. Neuropsychopharmacol.20(Suppl. 3), S587 (2010).